Translational Development Acquisition Corp (TDAC) Fair Value & Analysis
Financial Services · US · Market cap $208M
Translational Development Acquisition Corp
TDAC · US
Fair value as of: Jul 27, 2026
From 6 valuation models · updated 14 days ago
Share price +1.5% over the past month.
Below-average quality, and screening another 67% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case ($4.55). The favourable scenario is already priced in.
- Weak quality (29/100) and above fair value at the same time, the margin of safety is missing on both counts.
- For a financial, book-value and earnings-based methods matter more than a cash-flow DCF, which fits banks and insurers poorly.
Price vs Fair Value (18 months)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 27, 2026.
How to read this chart
18‑month range $10.00 – $10.87 · fair‑value band $2.73 – $4.55 · the $10.86 price screens above the $3.64 fair value. Dashed = 300-day average. As of Jul 27, 2026.
Analysis
Translational Development Acquisition Corp (TDAC) currently trades at $10.86, while our model-based Fair Value estimate is $3.64, implying the stock looks roughly 66.5% overvalued today. The Quality Score stands at 29/100 (below-average quality), in the Financial Services sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
The stock trades on a trailing P/E of 38.4. Fundamentals as of Jul 27, 2026
Our scenario range runs from $2.73 (bear case) to $4.55 (bull case); at $10.86, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 6% above its 52-week low, currently above its 200-day average. For context, the median of 10 Financial Services peers we cover trades at -61% fair-value upside, at -67%, TDAC screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 6 models by family
Widest divergence: Asset-Based ($6.08) versus Earnings-Based ($1.65). Highest evidence: P/E Multiple (63).
Notify me when TDAC reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
Figures from reported company fundamentals · as of Jul 27, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 34 · Market factors (momentum, volatility) 67
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Translational Development Acquisition Corp. does not have significant operations. The company intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. Translational Development Acquisition Corp.
Full company description
Translational Development Acquisition Corp. does not have significant operations. The company intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. Translational Development Acquisition Corp. was incorporated in 2022 and is based in New York, New York.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2025 · reported fiscal years
Translational Development Acquisition Corp reported revenue of $0 in FY2025 versus $0 in FY2023. Reported net income was $6.4M in FY2025.
TDAC screens 67% overvalued. Compare with The Coca-Cola Company →
Peer Group
Shell Companies · 70 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Shell Companies median · lower = cheaper
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Shell Companies stocks, each showing price versus our Fair Value estimate (as of Jul 27, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| The Coca-Cola Company COLA | C$27.96 | C$10.91 | -61% |
| Lionheart III Corp LION | $13.47 | $18.15 | +35% |
| Agriculture & Natural Solutions Acquisition Corporation ANSC | $11.45 | $4.13 | -64% |
| AA Mission Acquisition Corp AAM | $0.0320 | $0.0314 | -2% |
| GP-Act III Acquisition Corp GPAT | $10.91 | $4.30 | -61% |
| Berto Acquisition Corp TACO | $10.48 | $2.73 | -74% |
| Axiom Intelligence Acquisition Corp AXIN | $10.29 | $1.46 | -86% |
| Bold Eagle Acquisition Corp BEAG | $10.67 | $4.00 | -63% |
| Lionheart Holdings CUB | $10.80 | $5.06 | -53% |
| Graf Global Corp GRAF | $10.82 | $3.63 | -66% |
Compare Translational Development Acquisition Corp with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Financial Services stocks →
Frequently asked questions
Is Translational Development Acquisition Corp (TDAC) overvalued or undervalued?
What is the fair value of TDAC?
What is the quality score of TDAC?
What is the net profit margin of TDAC?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Translational Development Acquisition Corp and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.